| Designation | Director, Radiation Oncology |
| Language(s) | English / Hindi |
| Areas of Expertise | Radiation Oncology |
+91-9410816252
dramit2001@gmail.com
Education + Trainings
| Aug. 1995 - Dec. 2000 | M.B.B.S. from Dr. V.M. Medical College, Sholapur |
| Feb. 2002 - Feb. 2005 | M.D. Clinical Oncology from Tata Memorial Hospital, Mumbai (guide-Dr. K.A. Dinshaw [Past Director, Tata Memorial Hospital, Mumbai]) |
| Oct. 2005 | Cleared D.N.B. examination in Radiation Oncology with finals conducted at PGIMER, Chandigarh |
| Mar. 2005 - Mar. 2006 | Senior Resident, Dept of Clinical Oncology, Tata Memorial Hospital, Mumbai |
| Mar. 2006 - Mar. 2007 | Clinical Research Fellow in NeuroOncology & Stereotactic Radiosurgery Unit, Tata Memorial Hospital, Mumbai |
| Apr. 2007 - Aug. 2007 | Clinical Assistant & Research Associate, Dept of Clinical Oncology, Nanavati Hospital, Mumbai |
| Oct. 2007 - Jul. 2011 | Consultant Radiation Oncologist, SMH-Curie Cancer Centre, Shanti Mukand Hospital, New Delhi |
| Jul. 2011 - Dec. 2012 | Senior Consultant, Fortis International Cancer Centre, Noida |
| Jan. 2013 onwards | Head, Dept of Radiation Oncology, Valentis Cancer Hospital, Meerut |
| Training in High precission Radiation therapy techniques at Accuray centre for education, Medison USA | |
| Training in High precission Radiation techniques at Maimi Cancer Institute, Maimi USA |
Experience
Research At TMH
Research Associate for “Phase III randomized trial of stereotactic conformal radiotherapy vs conventional radiotherapy in pediatric low grade brain tumors, (Principal Investigator- Dr. Rakesh Jalali; Neurocognitive data of this trial presented in ASCO 2008).
Temozolomide, concurrent and adjuvant in glioblastoma multiforme at TMH: A prospective experience.
Prospective study of safety and efficacy of Temozolomide in pediatric brainstem gliomas and co-relation with FDG-PET scans (presented at WFNO, Japan 2006).
Analysis of palliative efficacy of Hemibody Irradiation for bony metastases in 70 patients at single institution.
Role of Three Dimensional Radiotherapy in Pituitary Adenomas.
Part of analysis of patterns of outcome of carcinoma cervix from 1996-2000.
Phase II trial of 2-deoxyglucose with hypofractionated radiotherapy in glioblastoma multiforme.
Research At Nanavati Hospital
Research Associate for “Phase III randomized trial of hyperthermia with radiotherapy vs hyperthermia alone in advanced head and neck cancer” at Nanavati Hospital sponsored by ICMR.
Research Associate for “Randomized phase III trial of radiotherapy with 2- deoxyglucose vs radiotherapy alone in glioblastoma multiforme.
Major Affiliations
Active Member of American Association of Cancer Research (AACR).
Active Member of American Society of Radiation Oncology (ASTRO).
Currently, one of the Referee of Journal of Cancer Research and Therapeutics, the official journal of Association of Radiation Oncologists of India (AROI).
Founder Member of Indian Society of Neuro-Oncology (ISNO).
Member of Association of Radiation Oncologists of India (AROI)
Member of Indian Co-operative Oncology Network (ICON).
International Ventures
Presented a paper in the annual meeting of American Association of Cancer Research in Apr 2018 at Chicago
Presented a paper in the annual meeting of American Association of Cancer Research (AACR) in Apr 2011 at Orlando.
Presented a poster in 2nd Worldwide Innovative Network (WIN) Consortium in Personalized Medicine at Paris in July 2010.
Attended AACR-EORTC meeting on Molecular Targets & Therapeutics in Boston, USA in Nov 2009.
On the list of Active researchers of Medical Research Council (MRC-CTU), U.K. Involved during feasibility study of BR-12 trial for “Temozolomide for Anaplastic Gliomas” initiated at TMH.
Attended ASCO 2009 at Orlando, Florida, USA in May 2009.
Fellow of European School of Oncology and have attended ‘Educational Convention at Lugano, Switzerland, July 2009.
Publications
Management of pituitary adenomas in “Evidence Based Management Guidelines Addressing Special Issues”; book released at EBM (Feb) 2006 conference organized by Tata Memorial Hospital and European Society of Therapeutic Radiology and Oncology (ESTRO)”.
Primary intramedullary primitive neuroectodermal tumor of the cervical spinal cord. Jain A; Jalali R; Nadkarni TD; Sharma S. J Neurosurg Spine (United States) 2006; 4(6):497-502.
Role of histopathology in predicting outcome of medulloblastoma treated at a single institution. Suash Sharma, Mahendra Parage, Rakesh Jalali, Amit Jain, Shubhada Kane, Rajiv Sarin, and P. Kurkure. UICC World Cancer Congress 2006 USA; Bridging the Gap: Transforming Knowledge into Action.UICC techprogramP7594.
In regards to Carr et al.: Coronary artery disease after radiotherapy for peptic ulcer disease. Munshi A; Jain A; Jalali R, Budrukkar A. Int J Radiat Oncol Biol Phys 2006;61:842-850.
A new indication of sildenafil in medicine: Hypoxic cell sensitizer for penile cancer. Huilgol Nagraj G, Jain Amit. Journal of Cancer Research and Therapeutics 2006;2(3):132-135.
6. Review of “Textbook of radiation oncology: Principles and practice”. Jain A. Journal of Cancer Research and Therapeutics 2006; 2(2):85.